Beyond Next Ventures

Beyond Next Ventures invests in early-stage deep-tech and life-science companies from Tokyo, with checks of $1M to $5M at pre-seed, seed, and Series A. The firm has built itself around academic spinouts and technical founders coming out of Japanese research institutions, and it operates with the patience that science-heavy investing requires. Pitches that lead with technical depth and a credible commercialization path tend to land; pitches that overpromise on timeline rarely survive the second meeting.

The healthcare thesis spans biotech, medical devices and medtech, and AI and machine learning in healthcare. Beyond Next is comfortable with companies that need years to clear preclinical work or regulatory milestones, provided the underlying science is differentiated. The firm is also active in software-driven healthcare opportunities where Japanese clinical or industrial assets give the company a structural edge. The portfolio leans toward companies with strong academic founders, often paired with operators recruited later as the business matures, and Beyond Next is willing to play a long role in that team-building process.

Check sizes of $1M to $5M let Beyond Next lead or co-lead pre-seed and seed rounds and follow on into Series A. The geographic focus is Japan, with selective exposure to Japanese-connected companies operating internationally and to non-Japanese companies that want to commercialize in Japan. Founders should expect granular questions on regulatory strategy and clinical validation, and the firm will frequently bring in advisors from Japanese pharma and medtech companies during diligence. Pre-revenue and pre-clinical companies are welcome if the science holds up.

The team includes investors with backgrounds in scientific research, operating roles at Japanese pharma and medtech companies, and venture investing. Beyond Next also operates an entrepreneur-in-residence and incubator program that pairs scientific founders with operating talent, which has produced several portfolio companies and gives the firm visibility into deals before they formally exist.

Beyond Next Ventures’ working style is patient and engaged. Partners take active roles in helping spinouts build out commercial leadership, navigate Japanese regulatory pathways, and access industry partners for licensing or distribution. The firm has a track record of supporting portfolio companies through multiple financings and into international expansion, often leveraging Japanese strategic acquirers as both customers and acquirers. Founders coming out of Japanese academic medicine or industrial life sciences, or international founders looking for a Japan-focused partner with patience for science timelines, will find Beyond Next a serious option. Those running short-cycle software businesses or expecting fast revenue ramps should look elsewhere.